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Abstract: Although antiretroviral drug resistance is common in treated HIV infected individuals, it is not a consistent 
indicator of HIV morbidity and mortality. To the contrary, HIV resistance-associated mutations may lead to changes in 
viral fitness that are beneficial to infected individuals. Using a bioinformatics-based model to assess the effects of 
numerous drug resistance mutations, we determined that the D30N mutation in HIV-1 protease had the largest decrease in 
replication capacity among known protease resistance mutations. To test this in silico result in an in vivo environment, we 
constructed several drug-resistant mutant HIV-1 strains and compared their relative fitness utilizing the SCID-hu mouse 
model. We found HIV-1 containing the D30N mutation had a significant defect in vivo, showing impaired replication 
kinetics and a decreased ability to deplete CD4+ thymocytes, compared to the wild-type or virus without the D30N 
mutation. In comparison, virus containing the M184V mutation in reverse transcriptase, which shows decreased 
replication capacity in vitro, did not have an effect on viral fitness in vivo. Thus, in this study we have verified an in silico 
bioinformatics result with a biological assessment to identify a unique mutation in HIV-1 that has a significant fitness 
defect in vivo. 
Keywords: HIV-1, replication capacity, bioinformatics, Bayesian, variable selection, exchangeable on subsets, prior model 
selection, in vivo validation. 
INTRODUCTION 
  The rate of HIV-1 replication and mutation in infected 
individuals is remarkable and alarming [1-3]. During 
antiretroviral treatment there is a dynamic interplay of drug-
resistance and fitness occurring within the virus population. 
It has been proposed that reduced viral fitness of HIV-1 can 
result in slower disease progression in vivo due to the 
decreased pathogenic ability of the virus [4-6]. Viral fitness 
in this case is defined by the ability of a virus to replicate in 
vivo and produce pathologic changes in host tissues. While it 
is difficult to directly assess viral fitness in vivo, the relative 
replication capacity (RC) of a viral mutant may be 
determined using in vitro cell culture models by examining 
how the virus replicates when compared to a virus without 
any mutations (wild-type virus) [4, 7, 8]. Viral fitness in vivo 
and observed RC in vitro are clearly linked; however, there 
is a lack of direct evidence that certain drug-resistance 
mutations actually confer a defect in viral fitness in vivo in 
infected persons. 
  In the clinical setting, combination antiretroviral therapy 
(ART) often fails to completely and durably suppress plasma 
levels of HIV-1 RNA [9-12] and the viral load may rebound. 
Virologic failure is often a consequence of a series of 
mutations in HIV that decreases the susceptibility of the 
virus to antiretroviral agents. It has been shown that drug-
resistant HIV often has lower RC in vitro than wild-type   
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virus [4, 7, 8, 13]. Treatment interruption of ART in patients 
leads to the re-emergence of archived wild-type virus that 
has a higher RC than the circulating drug-resistant virus and 
is associated with higher viremia and decreased CD4 T-cell 
counts [14, 15]. In contrast, patients who remain on their 
ART regimen despite ongoing viral replication may have 
stable CD4 counts and stable viremia [5, 16]. In one report, 
only 36.8% of patients experienced a decrease in CD4 counts 
to pre-therapy levels while remaining on a failing ART 
regimen for 3 years [16]. Similarly, Barbour et al. [17] found 
patients who remained on a failing regimen had stable RC, 
viremia and CD4 counts. These studies suggest that HIV is 
subject to genetic bottlenecks where it cannot create further 
resistance without sacrificing its ability to replicate. 
  Decreases in viral RC due to mutation have been well-
characterized in vitro, although alterations in fitness in vivo 
is often correlative due to the lack of use of a controlled 
experimental system during these studies [4, 7, 8, 13, 17-20]. 
It has been shown that certain mutations cause a substantial 
decrease in RC in vitro relative to wild-type strains. 
However, there also exist mutants that have similar or even 
higher replication capacity than wild-type [21]. The D30N 
mutation in the protease (PR) gene involves a GAT to AAT 
mutation that is well-characterized and specific to the 
protease inhibitor nelfinavir (NFV) [22, 23]. The D30N has 
been identified to biochemically alter viral protease activity 
in heterologous cleavage studies [7, 13, 18, 23-25]. The 
M184V mutation in the reverse transcriptase (RT) gene, 
which causes primary resistance to lamuvidine (3TC), has 
been extensively studied and is common in treated patients 
[6, 26-28]. Viral isolates with the M184V mutation in RT 226    The Open Medical Informatics Journal, 2010, Volume 4  Kitchen et al. 
have lower RC than viral isolates without the mutation [17]. 
In one study, HIV infected individuals with significant ART 
drug resistance were randomized to receive 3TC or to stop 
ART completely; those receiving 3TC alone experienced a 
lower increase in viral load, a slower rate of decline in CD4 
T cell percentage, and fewer adverse clinical events related 
to HIV infection [26]. 
  Assessing the relative impact of mutations on HIV fitness 
is difficult because there are often many more parameters 
than there are data. Previously we described an informatics-
based method to identify the relative fitness cost of 
mutations in protease using a Bayesian hierarchical model 
[29]. Using this model we found mutations in protease that 
had a relatively large decrease in viral RC. However, it is 
unknown if the in silico results correspond to an actual in 
vivo fitness decrease. 
  The effect of mutations on viral fitness and pathogenicity 
often cannot be determined in vitro; however, the SCID-hu 
mouse model allows direct assessment in human tissue in an 
in vivo setting. The SCID-hu mouse model of HIV infection 
is well described and has been used to examine the 
mechanisms of viral pathogenesis in primary human 
lymphoid tissue [8, 30]. We and others have found that 
HIV-1 directly injected into human thy/liv implants in 
SCID-hu mice results in reproducible infection and severe 
depletion of human cells bearing the CD4 molecule [30-32]. 
Stoddart et al. [8] examined viral fitness in 8 clinical isolates 
compared with HIVNL4-3, however none of these isolates 
contained the D30N mutation. They determined that while 
the RC of PI-resistant strains of HIV-1 in peripheral blood 
mononuclear cells (PBMCs) was moderately impaired 
compared to wild-type (WT) virus, the RC of PI-resistant 
strains  in vivo was highly impaired. The observation that 
differences in replication between PI-resistant strains and 
WT stains were seen in vivo in the SCID-hu mouse and not 
in vitro in PBMCs indicates that the SCID-hu mouse is an 
excellent model system to assess the fitness of viruses with 
different antiretroviral drug resistance mutations in primary 
human tissue. In contrast to other studies with patient 
isolates [8, 33], we explicitly tested specific mutations found 
a priori to have a fitness effect. In the current study, we 
utilized results from a bio-informatics model and then 
utilized in vitro tissue culture and the in vivo SCID-hu mouse 
model to determine if this mutation confers a biological 
fitness defect. This study demonstrates the synergistic 
possibilities in translational research and validates a unique 
drug resistance mutation in HIV-1 that confers an in vivo 
fitness defect in the virus. 
METHODS 
Bioinformatics Analysis 
  We used a Bayesian hierarchical model to determine the 
relative replication capacity effect of mutations in 161 
genotype-phenotype pairs of HIV-1 protease (described in 
[29]). Because we have a much greater number of 
parameters than data points (large p, small n), prior 
specification is critically important. Fortunately, there exists 
a wealth of information elucidating links between HIV 
replication and specific mutations based on site-directed 
mutagenesis and drug-resistance studies. Bayesian methods 
allow us to explicitly take into account what is known a 
priori about mutational patterns in HIV-1. The idea is to 
provide priors with both shrinkage and variable selection 
components. Let  yi  be the continuous fitness phenotype for 
the i
th HIV-1 sequence (Y = (y1,...,yn)'). Let  xij  represent 
the  j
th codon position for the i
th sequence 
( Xj = (x1j,...,xnj)'). In this case the  xj ’s are 0/1 indicators 
of a mutation away from wild-type at each codon position 
along the protease genome. The informatics problem is to 
find the set of  Xj ’s that are contributing to the fitness 
phenotype. Because the parameter space is much larger than 
the number of sequences, backwards and forward selection 
using conventional regression methods are unlikely to yield 
useful results. Kuo and Mallik [34] created a class of prior 
that has both a shrinkage and a selection component where 
all coefficients are exchangeable. Following Kuo and Mallik 
the prior parameters are specified by assuming all regression 
coefficients have the same prior. There are two parts to this 
prior, the  j  is the model selection part and the prior on the 
regression coefficient  j  is the shrinkage component.  j , 
the prior mean and variance of the regression coefficient, is 
modeled as a Normal with hyperpriors on the mean and 
variance which are fixed. The  j,( j ~ Bernoulli()) , is a 
binary indicator function for the presence of a fitness effect 
on the regression coefficient, (which then becomes  j j ) in 
the model. This prior is the same for all regression 
coefficients and thus all of the  xij 's are exchangeable. Fig. 
(1A) illustrates this prior. This model is scientifically 
uninformative in that each codon position has the same prior 
effect on fitness. We call this Model 1, the uninformative 
prior. 
  Site-directed mutagenesis and HIV-1 drug-resistance 
studies have gathered a wealth of information on identifying 
codon positions that appear to have an in vitro effect on 
fitness. To incorporate this information into our model we 
generalize our KM priors to allow for subsets of codon 
positions whose effects are exchangeable within the subset 
(the Exchangeable on Subsets Prior (ESP)). That is codons 
within the same set have the same prior while codons in 
different subsets have different priors. To see how this might 
work, we could allow a set of codons that site-directed 
mutagenesis has implicated as having a fitness effect to have 
a higher probability of inclusion (higher  ) and a higher 
prior mean fitness effect (through the mean and variance 
hyperparameters of j ) that codons not in this set. All of the 
codons in this selected subset are exchangeable, i.e. have the 
same prior. However, codons that are not in this subset could 
have a prior  j that has a lower probability of inclusion, , 
and a smaller fitness effect,  j . Fig. (1B) illustrates this ESP 
prior for when there are 4 different subsets. However the 
scientific literature uses different methods to determine 
importance and although there is general agreement for 
certain codon positions, there is not a consensus for all In Vivo Validation of a Bioinformatics Tool  The Open Medical Informatics Journal, 2010, Volume 4    227 
positions. Because of this, we create 3 ESP priors based on 3 
relevant papers in the HIV-1 literature. 
(A) 
 
(B) 
 
Fig. (1). Prior illustration for the models. For each codon position j, 
the column shows j, the prior 0/1 indicator if codon j is important 
to the fitness phenotype. The curve shows the prior distribution on 
the regression coefficient j. (A) Model 1, the uninformative prior. 
All codon positions have the same prior. (B) The Exchangeable on 
Subsets Prior (ESP). In the figure, 4 subsets are shown. Each codon 
within a subset has the same prior j and prior distribution on j. 
Different subsets have different values for the priors on the j’s and 
j’s. The four subsets are shown in different colors. 
  Specifically, we created a prior based on the paper by 
Swanstrom and Erona [35], a prior based on the paper by 
Foulkes and DeGruttola [36], and one based on Loeb et al. 
[18]. For each paper a model is constructed in which all 
codon positions identified as having a fitness effect are 
deemed important. These codon positions are all given the 
same prior with high inclusion probability and higher prior 
fitness effects. Codons that are not identified in the paper are 
deemed unimportant and are all given priors with low values 
of rho and diffuse j ’s centered around zero. To assess the 
consensus of positions we created another ESP prior where 
each model (the 3 literature based models and the 
uninformative Model 1) “voted” for a specific codon to be 
included in the “important” set and that codon was weighted 
according to the number of votes. In the voting model there 
were 4 classes of priors according to the number of votes a 
codon position received: 0, 1, 2, 3 or 4. Codons with more 
votes had a higher probability of inclusion, and beta 
coefficients with larger fitness effects. 
  To choose which prior fit the data best we used Prior 
Model Selection (PMS). In brief, we used Gibbs sampling to 
generate draws from the posterior distribution  f(, | y)of 
each of the 5 models. The marginal likelihood of Y, 
m(y) = f(y |)()/( | y), was calculated using Chib’s 
[37] method; where  represents the parameters and   
represents the prior. Each model was run 10 times to obtain 
an estimate of the standard deviation of the log marginal 
likelihood for each model. Bayes Factors were calculated 
from the difference of the average log marginal likelihood 
values and were used to compare the models. To determine 
the  in vivo effect in the SCID-hu mouse model, we 
conducted a power analysis to determine the number of mice 
that would be required in each group. The study was 
powered to detect a difference in the D30N groups (D30N 
and D30N + M184V) versus control (wild-type). The effect 
size of the power calculations were based on the results of 
the statistical model presented in Kitchen et al. [29]. For 
each mouse, the cumulative area under the curve for log 
HIV-1 RNA viral burden and total CD4+ thymocyte count 
were calculated. Groups were compared using the two-sided 
Wilcoxon Rank Sum Test. Groups were also compared over 
time using a nonlinear mixed effects model. Group by time 
comparisons were made using the Wilcoxon Rank Sum test 
with p-values adjusted for the overall type 1 error rate using 
a Bonferroni correction. 
Generation of Drug-Resistant Viral Stock 
  Viral mutants were generated by the introduction of the 
D30N and M184V mutations into a molecularly cloned 
strain of HIV (HIV-1NL4-3) by site-directed mutagenesis. 
Viral stocks were prepared by electroporation of CEMx174 
cells with plasmid DNA encoding the genome of wild-type 
and mutant viruses. Virus was harvested in culture 
supernatant 2 and 3 days following electroporation and 
quantitation of p24 gag was performed by enzyme-linked 
immunosorbent assay (ELISA, Coulter, Hialeah, Florida). 
Viral titers were determined through a standard limiting 
dilution assay on CEMx174 cells. 
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In Vitro Viral Growth 
  Freshly isolated peripheral blood mononuclear cells 
(PBMC) were obtained in the form of leukopacks from 
anonymous donors by the UCLA AIDS Institute Virology 
Core in accordance with IRB protocols. PBMCs were 
purified by Ficol purification and cells were then stimulated 
for three days with phytohemagglutin (PHA)(1 
microgram/ml)(Sigma) and IL-2 (100 units/ml)(R&D 
Systems, Minneapolis, MN). Cells were then infected, 
separately, with each indicated virus at a multiplicity of 
infection (MOI) of 0.003 in a volume of 1 ml for two hours 
at 37 degrees. Cells were then cultured at a concentration of 
1 x 10
6/ml and at the indicated times 100 microliters of 
supernatant was removed and replaced with fresh medium. 
Viral supernatant was then placed in PBS containing 1% 
Triton X-100 and p24 levels were quantitated by ELISA, as 
described above. 
SCID-hu Mice 
  SCID-hu thy/liv mice were constructed by implanting 
human fetal thymus and liver under the kidney capsule of 
C.B.17 SCID mice as described [28, 34]. Thy/liv implants 
(n=5 mice per group) were infected by direct injection of 100 
infectious units of either wild type HIV-1NL4-3 or HIV-1 NL4-3 
containing the D30N, the M184V, or both the D30N and 
M184V mutations or were mock infected with medium 
alone. At the specified time points, thy/live implants were 
biopsied utilizing survival surgery procedures as described 
[28, 34]. 
Flow Cytometry 
  Single cell suspensions were made from the biopsied 
tissue and analyzed by flow cytometry for the expression of 
CD45, CD3, CD4, and CD8 similar to that described [35, 
36]. Cells were run on a Coulter FC500 (Coulter, Hialeah, 
FL) flow cytometry and data was analyzed by FlowJo 
software (Treestar, Ashland, OR). Depletion of CD4+ cells 
(CD4+CD8+ and CD4+CD8- thymocytes) was determined 
by comparison of cells from HIV infected implants to mock-
infected controls. 
Quantitative DNA PCR 
  A fraction of cells was removed and DNA was purified 
as previously described [38, 39]. Quantitation of proviral and 
cellular DNA was performed with real time quantitative PCR 
using primers specific for human beta globin sequences and 
full-length HIV reverse transcripts (the long terminal repeat-
gag junction) as described by [40]. 
RESULTS 
  Utilizing a data set of 161 of genotype/phenotype pairs 
(described in [29]), we used a Bayesian hierarchical model to 
determine the relative effects of mutation in silico. The 
priors that were used included an uninformative prior across 
the whole protease genome, three literature based ESP priors 
and a voting ESP prior whereupon each model “voted” for a 
codon position. We then incorporated prior model selection 
(PMS) to choose among our priors. The voting prior had the 
smallest log marginal likelihood of all the models and testing 
the uninformative model versus the voting model decisively 
rejected the uninformative model (log Bayes Factor=91.32). 
Using this model as our final model, we were able to assess 
the relative cost of each mutation in protease, in terms of 
RC. The model found that the D30N mutation had the largest 
decrease in RC relative to other resistance-associated 
mutations suggesting that this mutation may have clinical 
benefit in prolonging disease progression by conferring a RC 
defect. Table 1 lists the regression coefficient estimates and 
the 95% credible interval of the top 5 drug-resistance 
associated mutations in protease. 
Table  1.  The Estimated Fitness Effect, E[|y] and the 
Corresponding 95 Percent Credible Interval for the 
Top 5 Drug-Resistance Associated Mutations from 
the Final Best Fitting Model 
 
Codon  
Position 
Estimated Fitness  
Effect 
95% Credible  
Interval 
D30N -16.72  (-30.32,  -2.92) 
V77I -13.49  (-22.34,  -4.62) 
V82A/F/T/S -16.61  (-25.40,  -5.35) 
I84V/A/C -13.11  (-23.28,  -0.81) 
L90M -12.60  (-23.25,  -1.91) 
 
  To assess the effects the in silico identified D30N PR and 
the previously implicated M184V RT mutation in infectivity 
of HIV-1 we assessed viral titers of molecularly clones 
variants of HIV-1NL4-3 containing these mutations in a 
standard limiting dilution assay. HIV-1NL4-3 wild type, HIV-
1NL4-3 with the D30N mutation, HIV-1NL4-3 with the M184V 
mutation, and HIV-1NL4-3 containing both the D30N and 
M184V mutations all had a titer of 300 picograms per 
infectious unit, indicating that the presence of the mutation 
in the drug resistant viruses did not affect initial viral 
infectivity. We then compared the ability of theses viruses to 
replicate in PHA-activated PBMCs. Cells were infected at a 
relatively low multiplicity of infection (MOI) to detect and 
magnify differences in the ability of the virus to replicate 
over multiple rounds of infection. We found that the virus 
containing the M184V mutation displayed slightly delayed 
replication kinetics while the viruses containing the D30N 
alone and in combination with M184V and the double 
mutant had a more dramatic decrease in viral replication as 
compared to the wild-type virus (Fig. 2). In all, these data 
indicate that mutations do not alter the infectivity of the 
virus, but reduce viral RC. 
  To examine the effects of these mutations on viral fitness 
and pathogenesis in vivo, we examined the accumulation of 
HIV DNA and the level of virus-induced CD4+ thymocyte 
depletion over time using the SCID-hu mouse model. 
Thy/liv implants were initially infected with equivalent 
amounts of infectious units of wild type, D30N-containing, 
M184V-containing, and both D30N and M184V containing 
HIV-1NL4-3 in parallel and the effects of the virus were 
examined at 3, 5, and 7 weeks following infection. Proviral 
DNA was detected in mice infected with each different virus 
within three weeks post infection (Fig. 3). Infection of 
thy/liv implants with wild type (NL4-3) produced time 
dependent increases in log HIV-1 DNA levels. Infection of 
mice with HIV-1NL4-3 containing the M184V mutation 
produced similar viral kinetics as the wild type virus. The In Vivo Validation of a Bioinformatics Tool  The Open Medical Informatics Journal, 2010, Volume 4    229 
average cumulative area under the curve was not 
significantly different for M184V versus wildtype. Mice 
infected with HIV-1NL4-3  containing the D30N or 
D30N+M184V mutation, however, had barely detectable 
viral DNA at all three time points. Mice harboring HIV-1NL4-
3 containing the D30N mutant strains had significantly lower 
levels of HIV RNA than the wildtype or M184V alone 
groups (P=0.001). There was no statistically significant 
difference in HIV DNA levels between the D30N and the 
D30N+M184V infected group at any time point. 
 
Fig. (2). Replication kinetics of wild-type, M184V-containing, 
D30N-containing, and M184V and D30N-containing viruses in 
PHA-stimulated PBMC. Viral p24 antigen production was assessed 
at days 5 and 8 post infection. The results shown are representative 
of 3 independent experiments with PBMC derived from different 
donors. 
 
Fig. (3). Viral replication of wild-type, M184V-containing, D30N-
containing, and M184V and D30N-containing viruses in vivo. 
Thy/liv implants were infected, separately (n=5 mice per group), 
with identical amounts of infectious units of each virus. Implants 
were analyzed following biopsy of infected tissue by quantitative 
PCR for HIV proviral DNA at 3, 5, and 7 weeks following 
infection. The amounts of proviral DNA are provided as copies of 
full length proviral DNA per 100,000 cells, as determined by the 
use of HIV and human -globin specific primers and quantitative 
comparison to known controls. Mock infected controls were 
negative for HIV proviral DNA (not shown). 
  Cellular depletion of CD4 bearing thymocytes which is 
indicative of viral pathogenesis, primarily in the CD4+CD8+ 
population, was observed in mice infected with wild type 
HIV-1 NL4-3 and the M184V containing strains within 5 
weeks following infection (Fig. 4). Seven weeks post 
inoculation, we found profound CD4+ thymocyte depletion 
in the mice infected with wild-type virus or the virus 
containing the M184V mutation alone. The level of 
depletion in these two groups was significantly greater than 
the level of depletion found in mice infected with strains that 
included the D30N mutation (p=0.001). In fact, mice 
infected with strains containing the D30N mutation 
(including the double mutant) were not statistically different 
from the mock infected mice in terms of percent total CD4+ 
thymocytes. The differences in percent total thymocytes 
between mock and the two D30N groups were not 
significant at any time point (even without adjusting for 
multiple comparisons). Mice infected with the M184V 
mutation alone had a profound depletion in thymocytes 
compared to mock infected mice (p=0.027) and was not 
significantly different from the depletion found in mice 
infected with wildtype virus, indicating that the D30N is 
primarily responsible for the attenuated virulence. 
DISCUSSION 
  These results illustrate the utility of biostatisticians and 
biologists working together and demonstrate the synergy 
possible with translational studies. This work was prefaced 
by a thorough examination of protease mutations in a 
bioinformatics system whereby the D30N mutation was 
found to have a profound effect on in vitro replication. To be 
able to specifically attribute viral attenuation with the 
mutation, we constructed point mutants instead of using 
patient isolates that may have accrued mutations at other loci 
in the viral genome. Our results indicate that the D30N 
mutation has a substantial effect on the ability of HIV-1 to 
deplete thymocytes and to replicate in an in vivo system. 
  Our data clearly demonstrate that mutations in the HIV-1 
genome may differ greatly in their impact on HIV replication 
capacity and pathogenicity. Whereas the virus containing the 
M184V mutation alone conferred a RC defect in vitro, we 
did not find evidence for decreased pathogenicity of this 
virus  in vivo. In our experiments, mice infected with this 
mutant did not have statistically different viral loads or 
CD4+ thymocyte counts than mice infected with wild-type. 
In addition, the M184V did not enhance or inhibit viral 
replication or the ability of the virus to deplete thymocytes 
when coupled with the D30N mutation. There was no 
statistically significant difference between mice infected 
with the D30N mutant and those infected with the 
D30N+M184V double mutant at any time point. These 
studies demonstrate that RC results observed in vitro do not 
necessarily correlate with a defect in viral fitness in vivo. 
  Our results contrast from those described by Stoddard et 
al. who found that mice infected with a virus (210P) 
containing protease mutation at I54V and V82A had a higher 
level of viremia than mice infected with wild-type virus. 
However, comparison is difficult due to the presence of 
different mutations in the HIV protease (D30N versus 
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I54V+V82A), as well as the variability inherent in 
experiments employing SCID-hu mice in which a chimeric 
organ is created by engraftment of primary human tissues. 
Nonetheless, the differences in these results may also 
suggest that virus containing the D30N mutation is less able 
to replicate in the thymus than virus containing the V82A 
mutation (as is suggested by our bioinformatics model). The 
D30N mutation was chosen as it had the largest decrease in 
relative replication capacity. It is noteworthy that previous 
studies have shown that the V28A and the D30N mutations 
do no co-occur in the same genome [41-43]. 
  Although some patients experience the so called 
“discordant state” characterized by having both high viral 
loads and stable CD4+ T-cell counts, but there are many 
others who are concordant and have high viral loads and 
 
 
Fig. (4). Depletion of CD4-bearing cells following infection with wild-type, M184V-containing, D30N-containing, and M184V and D30N-
containing viruses in vivo. (A) CD4 versus CD8 flow cytometry staining profiles were determined on biopsied thy/liv tissue at the indicated 
times following infection with one of the four indicated viruses. Cells were stained with monoclonal antibodies (and their corresponding 
fluorochromes) to CD45 (FITC), CD8 (ECD), and CD4 (APC). CD4 and CD8 profiles of this population are given by gating on the human 
CD45+ population of cells. The percentages of cells in each quadrant are indicated. The data is representative of one mouse per group (total 
of 5 mice per group) of a total of three experiments. (B) Graphic representation of the percentage of total CD4+ cells in the respective thy/liv 
implants over time. 
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decreasing CD4 counts despite the presence of PI resistance 
mutations [5, 16, 44-46]. The latter state likely arises when 
HIV acquires compensatory mutations that increase its level 
of fitness and restore its ability to deplete CD4+ T-cells. The 
apparent lack of pathogenicity of the HIV-1 D30N mutant 
suggests that this mutation may represent a genetic “dead-
end” for the virus. Once the D30N mutation has been 
acquired, the virus may not be able to replicate well enough 
to return to wild-type fitness. There may be other genetic 
bottlenecks in the virus that can be capitalized upon to drive 
the virus into an unfit-state and preserve CD4+ T-cells, 
however further research is needed. 
  In people infected with clade B strains of HIV, those that 
harbor virus containing the D30N mutation often also have 
the L63P mutation. The L63P mutation was not identified as 
having a large fitness defect by our model, likely because the 
L63P mutation is prevalent in patients who are treatment 
naïve and is therefore not a drug-resistance mutation. 
Moreover, others have reported that the replication of a 
D30N containing variant was not significantly different from 
a L63P+D30N dual mutant [7]. Similarly, patients with the 
D30N mutation often develop the N88D/S mutation. N88D/S 
did not have a significant effect on fitness in the statistical 
model and was not tested. HIV variants with both the D30N 
and N88D mutation was also found to have decreased 
replication capacity in vitro, including subtype C strains [24, 
47, 48]. 
  There are several limitations to this study. Our analysis 
was based on examinations of mutations found in protease in 
HIV-1 clade B strains and our biologic experiments used 
viruses based on an HIV-1 clade B strain. Although the 
D30N has been identified as having an effect in vitro in 
HIV-1 clade C strains, it not known if the in vivo result is 
generalizable to other non-B clades and HIV-2. It is also 
possible that the D30N mutation might not be preferentially 
selected through nelfinavir treatment in non clade-B strains. 
Further there could be unaccounted variation in the human 
tissues used in the SCID-hu model that limits the 
generalizability of this finding. Further research needs to be 
done. 
  In conclusion, our results suggest the possibility of the 
existence of genetic bottlenecks in HIV-1 that select for 
mutations that diminish replication capacity and in vivo 
fitness to such an extent that the virus is unable to acquire 
compensatory mutations as well as deplete target cells. 
Further work is needed to find other possible dead-end 
mutations in regions of the genome that are targeted by other 
antiretroviral agents now under development or in initial use, 
such as inhibitors of the strand transfer activity of the HIV 
integrase protein. In all, this study validates a bioinformatics 
model tested by an in vivo system. 
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